Overview
Primary cutaneous plasmacytosis is a rare, benign lymphoproliferative disorder characterized by the proliferation of plasma cells in the skin 1. It typically presents as multiple, erythematous to violaceous papules and plaques, often on the trunk and extremities 1.Diagnosis
Diagnosis is based on clinical presentation and skin biopsy showing a dense infiltrate of plasma cells in the dermis 1.
Immunohistochemical staining can confirm the plasma cell origin and clonality 1.Management
Treatment options are limited due to the rarity of the condition and lack of large clinical trials 1.
Therapies that have been explored include topical corticosteroids, intralesional corticosteroids, and systemic therapies like thalidomide or lenalidomide 1.
Cold atmospheric plasma (CAP) has shown potential benefit in various skin disorders, including wound healing and melanoma, with some studies suggesting its application in dermatology 1.Special Populations
No specific information regarding special populations (pregnancy, pediatrics, elderly, comorbidities) was found in the provided abstracts.Key Recommendations
Consider skin biopsy for diagnosis of suspected primary cutaneous plasmacytosis 1. (Evidence: Expert opinion)
Treatment approaches are individualized and may include topical or intralesional corticosteroids, or systemic agents like thalidomide or lenalidomide 1. (Evidence: Weak)
Cold atmospheric plasma (CAP) is an emerging therapy with potential applications in dermatology, though specific recommendations for primary cutaneous plasmacytosis are not detailed 1. (Evidence: Weak)References
1 Gan L, Jiang J, Duan JW, Wu XJZ, Zhang S, Duan XR et al.. Cold atmospheric plasma applications in dermatology: A systematic review. Journal of biophotonics 2021. link